769
Views
23
CrossRef citations to date
0
Altmetric
Review Article

Maternal blood biomarkers and adverse pregnancy outcomes: a systematic review and meta-analysis

ORCID Icon, , , ORCID Icon, &
Pages 461-478 | Received 30 Jul 2018, Accepted 06 Jun 2019, Published online: 11 Sep 2019
 

Abstract

Background: Pregnancy is a vulnerable period for the mother and the infant and exposures to environmental chemicals in utero can influence neonatal morbidity and mortality. There is a momentum toward understanding and exploring the current maternal biological mechanisms specific to in utero effects, to improve birth outcomes. This study aims to examine the current understanding of the role of biomarkers that may be associated with term of pregnancy, infant birth weights and infant development in utero.

Methods: Electronic searches were conducted in PubMed, Embase, OvidMD, and Scopus databases; and all relevant research articles in English were retrieved. Studies were selected if they evaluated maternal blood plasma/serum biomarkers proposed to influence adverse birth outcomes in the neonate. Data were extracted on characteristics, quality, and odds ratios from each study and meta-analysis was conducted.

Results: A total of 54 studies (35 for meta-analysis), including 43,702 women, 50 plasma markers and six descriptors of birth outcomes were included in the present study. The random effect point estimates for risk of adverse birth outcomes were 1.61(95%CI: 1.39–1.85, p < 0.0001) for inflammation-related biomarkers and 1.65(95%CI: 1.22–2.25, p = 0.0013) for growth factor/hormone-related biomarkers. All subgroups of plasma markers showed significant associations with adverse birth outcomes with no apparent study bias.

Conclusions: The two subsets of plasma markers identified in this study (inflammation-related and growth factor/hormone-related) may serve as potentially valuable tools in the investigation of maternal molecular mechanisms, especially select pathways underlying inflammatory and immunological mediation in terms of modulating adverse infant outcomes. Future large, prospective cohort studies are needed to validate the promising plasma biomarkers, and to examine other maternal biological matrices such as cervicovaginal fluid and urine.

Acknowledgements

The authors acknowledge the reviewers for their comments on the manuscript. Their suggestions were helpful and contributed to the clarity and accuracy of our publication. The authors thank Christine Absi for technical assistance in collecting the data for this review.

Declaration of interest

The authors declare to have no conflict of interest. No funding was received specifically for this project. This critical review was conducted during the normal course of the authors’ employment using institutional funding. No outside funds were used to prepare the review. This review is professional work of the authors and the views expressed are not necessarily the views of their employers. None of the authors have appeared during the last 5 years in any regulatory or legal proceedings related to the contents of this paper.

Departmental funds were used to support the study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.